Patents by Inventor Christine E. Mclaren

Christine E. Mclaren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190038584
    Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
    Type: Application
    Filed: February 23, 2018
    Publication date: February 7, 2019
    Inventors: Eugene W. GERNER, Jason A. ZELL, Christine E. MCLAREN, Frank L. MEYSKENS, Jr., Hoda ANTON-CULVER, Particia A. THOMPSON
  • Patent number: 9937141
    Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: April 10, 2018
    Assignees: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Eugene W. Gerner, Jason A. Zell, Christine E. McLaren, Frank L. Meyskens, Jr., Hoda Anton-Culver, Particia A. Thompson
  • Publication number: 20160213634
    Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
    Type: Application
    Filed: September 1, 2015
    Publication date: July 28, 2016
    Inventors: Eugene W. GERNER, Jason A. ZELL, Christine E. MCLAREN, Frank L. MEYSKENS, Hoda ANTON-CULVER, Particia A. THOMPSON
  • Patent number: 9121852
    Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: September 1, 2015
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
    Inventors: Eugene W. Gerner, Jason A. Zell, Christine E. McLaren, Frank L. Meyskens, Jr., Hoda Anton-Culver, Patricia A. Thompson
  • Publication number: 20130217743
    Abstract: Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N1-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.
    Type: Application
    Filed: May 13, 2011
    Publication date: August 22, 2013
    Applicants: CANCER PREVENTION PHARMACEUTICALS, INC., CANCER PREVENTION PHARMACEUTICAL, INC, THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
    Inventors: Kavitha P. Raj, Jason A. Zell, Christine E. Mclaren, Eugene W. Gerner, Frank L. Meyskens, JR., Jeffrey Jacob